

# ADVAMED COVID-19 DIAGNOSTIC SUPPLY REGISTRY

AdvaMed members manufacture and ship instruments and high-quality tests that, together with key inputs from our colleagues across the testing ecosystem (e.g., personal protective equipment, plastics, swabs, etc.), serve as the backbone of supply for the U.S. testing response to COVID.

AdvaMed has created a comprehensive, national COVID-19 Diagnostic Supply Registry to support state and federal governments in their pandemic responses. AdvaMed and its members are fully committed to providing key data to policymakers and the public in our collective work mobilizing against the pandemic.


AdvaMed is leading this data tracking and analysis effort, driven by thirteen leading diagnostic manufacturers whose tests together comprise ~95% of the COVID-19 commercial tests on the market in the U.S.



## Key Data-Driven Summary of the U.S. COVID Testing Supply

Last updated July 31, 2020

- Over **100 commercial tests for COVID-19** have secured authorization under the FDA.
- Across leading COVID diagnostic manufacturers, roughly **100 Million<sup>1</sup>** Molecular COVID-19 tests have been manufactured and shipped to hospitals, public health and reference laboratories and other sites since March, including **~75M commercial tests** and **~25M extraction reagents**, a key input into non-commercial laboratory developed tests.
- Manufacturers have increased Molecular test production from **~600,000<sup>1,2</sup>** shipments per day at the start of May to just under **1 Million shipments per day<sup>2</sup>** by July 25<sup>th</sup> (data based on a four-week rolling average).
- Per public sources, daily Molecular tests run continue to grow rapidly as well, increasing by **~40%** to date in July vs. June's average, and reaching an all-time peak of over **800,000 tests per day<sup>3</sup>**. In total, **~50 Million** Molecular tests have been run in the U.S. since March.
- High-quality **Serology testing**, authorized by FDA, is now available at scale with industry **capacity to manufacture 100 million tests per month**.



Cumulative tests shipped<sup>1</sup>

**~100M**

Total Molecular tests shipped as of July 25<sup>th</sup>



1. Historical test numbers have been restated since the previous report, to include additional participant data  
 2. Averaged over latest 4 weeks to account for fluctuations in buying cycle  
 3. Averaged over the week to account for fluctuations by day of the week



AdvaMedDx



AdvaMed  
Advanced Medical Technology Association